{"filing":{"accession_number":"0001104659-26-072931","cik":"0001561921","ticker":"TELA","company_name":"TELA Bio, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"tm2617369d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926072931/tm2617369d1_8k.htm"},"events":[{"id":5288,"run_id":4635,"accession_number":"0001104659-26-072931","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"TELA Bio held its Annual Meeting of Stockholders on June 11, 2026, with voting results on four proposals: election of Class I directors (Capper, Rocchio, Plovanic), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a 3.5 million share increase to the 2019 Equity Incentive Plan.","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6242,"accession_number":"0001104659-26-072931","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2019 Equity Incentive Plan that increases authorized shares by 3,500,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves a material modification to the equity plan that governs director and officer compensation. The increase in authorized shares is material to investors assessing potential dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:08:11.728952+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6243,"accession_number":"0001104659-26-072931","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the final voting results from TELA Bio's Annual Meeting of Stockholders held on June 11, 2026, covering four proposals: election of Class I directors (Capper, Rocchio, Plovanic), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a 3.5 million share increase to the 2019 Equity Incentive Plan. The detailed vote tallies for each proposal are the core disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing governance and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:08:11.728952+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6242,"accession_number":"0001104659-26-072931","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2019 Equity Incentive Plan that increases authorized shares by 3,500,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves a material modification to the equity plan that governs director and officer compensation. The increase in authorized shares is material to investors assessing potential dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:08:11.728952+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-06-11"},{"id":6243,"accession_number":"0001104659-26-072931","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the final voting results from TELA Bio's Annual Meeting of Stockholders held on June 11, 2026, covering four proposals: election of Class I directors (Capper, Rocchio, Plovanic), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a 3.5 million share increase to the 2019 Equity Incentive Plan. The detailed vote tallies for each proposal are the core disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing governance and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:08:11.728952+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-06-11"}]}